Posted by Michael Wonder on 13 May 2021
Strongbridge Biopharma announces U.S. FDA filing acceptance of new drug application for Recorlev (levoketoconazole) for the treatment of endogenous Cushing’s syndrome
13 May 2021 - FDA Sets Prescription Drug User Fee Act target action date of 1 January 2022.
Strongbridge Biopharma today announced that the U.S. FDA has accepted for review the Company’s new drug application for Recorlev (levoketoconazole) for the treatment of endogenous Cushing’s syndrome.
